Pipeline Report

Updated February 1st, 2026

BuyandBill.com Analytics Pro Features

Unlock Full Access to
BuyandBill.com Analytics

Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.

You attempted to open: Drug Pipeline Report
10+ Years of Historical Pricing Data
Unlimited Access to All Drug Pages
Comparative & Historical Drug Pricing Reports
PriceDoctoRx Self-Administered Drug Pricing
Medicare & Medicaid Claims Data
Drug Pipeline Report
Check Out New Features
Comparative Pricing Reports

Search

Descriptive Alt Text

Filters

Showing results 809–816 of 4,419
Manufacturer ▼ Drug Name Indication Stage Status Route of Administration Drug Class
BeiGene Ltd. Tislelizumab (anti-PD1) plus ociperlimab (anti-TIGIT) - (AdvanTIG-204) Small cell lung cancer (SCLC) Phase 2 Data Released Intravenous Oncology
BeiGene Ltd. Tislelizumab - (Rationale-301) Hepatocellular carcinoma (HCC) Phase 3 Intravenous Oncology
BeiGene Ltd. Pamiparib (BGB-290) Maintenance Therapy Ovarian Cancer Phase 3 Oral Oncology
BeiGene Ltd. Tislelizumab - (RATIONALE 303) Non-small cell lung cancer (NSCLC) Phase 3 Intravenous Oncology
BeiGene Ltd. Tislelizumab Squamous non-small cell lung cancer (NSCLC) Phase 3 Intravenous Oncology
BeiGene Ltd. Tislelizumab - (RATIONALE 309) Nasopharyngeal cancer (RM-NPC) Phase 3 Intravenous Oncology
BeiGene Ltd. Tislelizumab and chemotherapy - (RATIONALE 304) Non-squamous non-small cell lung cancer (NSCLC) Phase 3 Intravenous Oncology
BeiGene Ltd. Tislelizumab and chemoradiotherapy Esophageal squamous cell carcinoma (ESCC) Phase 3 Trial Completed Intravenous Oncology